Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue 5, 1997, Pages 318-326

  Pakker, Nadine G ^a   Roos, Marijke T L ^a   Van Leeuwen, Remko ^b   De Jong, Menno D ^b   Koot, Maarten ^a   Reiss, Peter ^b,c   Lange, Joep M A ^b,c   Miedema, Frank ^a,d   Danner, Sven A ^c   Schellekens, Peter T A ^a,e  

^a Lab of Exp and Clinical Immunology

^b Natl AIDS Therapy Evaluation Center

^c Department of Internal Medicine

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e CENTRAL LABORATORY   (Netherlands)

Author keywords

Antiviral therapy; CD4 lymphocytes; HIV 1; T cell function; Viral RNA load

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY CD3; NEVIRAPINE; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 13144306121     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199712150-00002     Document Type: Article

References (41)

1. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquied immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987;316:61-6.
2. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
3. Melbye M, Biggar RJ, Ebbesen P, et al. Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. Ann Intern Med 1986;104: 496-500.
4. Gupta P, Kingsley L, Armstrong J, Ming Ding, Cottrill M, Rinaldo C. Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. Virology 1993;196:586-95.
5. + lymphocytes. Proc Natl Acad Sci USA 1994;91:1104-8.
6. Piatak M, Jr., Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
7. Mellors JW, Kingsley L, Rinaldo CR, Jr., et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
8. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
9. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.
10. Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995;123:641-8.
11. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996;276:105-10.
12. Phillips AN, Eron JJ, Bartlett JA, et al. HIV-1 RNA levels and the development of clinical disease. AIDS 1996;10:859-65.
13. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996;276:146-54.
14. Markowitz M, Saag MS, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-40.
15. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
16. Schellekens PThA, Roos MThL, De Wolf F, Lange JMA, Miedema F. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for AIDS in HIV-1 infected men. J. Clin Immunol 1990;10:121-7.
17. Miedema F, Meyaard L, Koot M, et al. Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev 1994;140: 35-72.
18. Bindels PJE, Krol A, Roos MThL, et al. The predictive value of T cell function in vitro and pre AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. J Infect Dis 1995;172:97-104.
19. Roos MThL, Miedema F, Koot M, et al. T-cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus (HIV)-infected asymptomatic individuals. J Infect Dis 1995;171:531-6.
20. + T cell count and function: Markers with reciprocal predictive value over time after seroconversion. AIDS 1997, in press.
21. Havlir D, Richman DD. Viral dynamics of HIV: Implications for drug development and therapeutic strategies. Ann Intent Med 1996;124:984-94.
22. Clerici M, Landay AL, Kessler HA, et al. Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J Infect Dis 1992;166: 723-30.
23. Clerici M, Roilides E, Butler KM, et al. Changes in T-helper cell function in human immunodeficiency virus infected children during didanosine therapy as a measure of antiretroviral activity. Blood 1992;80:2196-202.
24. Gruters RA, Terpstra FG, Lange JMA, et al. Differences in clinical course in zidovudine-treated asymptomatic HIV-infected men associated with T-cell function at intake. AIDS 1991;5:43-7.
25. Koot M, Schellekens PThA, Mulder JW, et al. Viral phenotype and T-cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J Infect Dis 1993;168: 733-6.
26. Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. AIDS 1994;8:313-21.
27. De Jong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966-70.
28. Bloemena E, Roos MThL, van Heijst JLAM, Vossen JMJJ, Schellekens PThA. Whole-blood lymphocyte cultures. J Immunol Methods 1989;122:161-7.
29. Van Lier RAW, Boot JHA, Verhoeven AJ, De Groot ER, Brouwer MA, Aarden LA. Functional studies with anti-CD3 heavy chain isotype switch variant monoclonal antibodies. J Immunol 1987; 139:2873-9.
30. Van Lier RAW, Brouwer M, Aarden LA. Signals involved in T-cell activation. T-cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur J Immunol 1988;18:167-72.
31. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. A rapid and simple PCR assay for quantification of human immunodeficiency virus type-1 RNA in plasma; application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
32. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type-1 selected during therapy. J Virol 1994;68:1660-6.
33. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-10.
34. Schmit J, Ruiz L, Clotet B, et al. Resistance related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538) AIDS 1996;10:995-9.
35. De Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid chage in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA 1996;93:5501-6.
36. Roederer M. T cell dynamics of immunodeficiency. Nature Med 1995;1:621-2.
37. Cameron B, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. (abstract LB6a). In: Program and abstracts of the third conference on retroviruses and opportunistic infections. Washington, DC. 1996.
38. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
39. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV) infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
40. Sanders ME, Makgoba MW, Shaw S. Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets. Immunol Today 1988;9:195-8.
41. Van Noesel CJM, Gruters RA, Terpstra FG, Schellekens PThA. Van Lier RAW, Miedema F. Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic HIV-infected men. J Clin Invest 1990;86:293-9.